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Brain Metastases
Background
A third of patients with solid malignancies develop brain metastases. 
Expected overall survival is 4-7 months depending on age, 
performance status, and extracranial disease. Standard treatment 
is controversial; however, the majority of patients receive whole-
brain radiation therapy at some point. Vorinostat (suberoylanilide 
hydroxamic acid, SAHA), an FDA-approved HDAC inhibitor, has 
been demonstrated to radiosensitize tumor cells in vitro, as assessed 
by both radiation-induced DNA damage and clonogenic cell survival 
(Munshi et al. Molecular Cancer Therapeutics 5, 1967-1974, 2006). 
We have shown that vorinostat downregulates key genes involved 
in double-strand DNA repair (Rad50, Rad51, XRCC2, XRCC3, 
XRCC6), as assessed by quantitative PCR. This suggests that the 
drug’s mechanism of radiosensitization is epigenetic coordinated 
inhibition of the DNA repair process. We hypothesize that the 
combination of vorinostat with whole-brain radiation therapy will 
be both safe and efficacious.
Methods
This is a dose escalation phase I investigational trial, based on 
Fibonacci 3+3 design. Whole-brain radiation is delivered in daily 
fractions of 2.5 Gy over 3 weeks (total dose 37.5 Gy) delivered 
through parallel opposed fields. Vorinostat is delivered once daily 
on days of radiation therapy. Dose levels: increase from 200 mg PO 
qd to 400 mg PO qd in subsequent patient cohorts, with an option 
de-escalate if 200 mg is found overly toxic. Expected total accrual: 
9-18 patients. Primary endpoint is tolerability; secondary endpoint 
is overall survival. Open to accrual at Thomas Jefferson University, 
Philadelphia PA; UT Southwestern Medical Center, Dallas, TX and 
Sheba Medical Center, Tel Aviv, Israel.
Study is supported by Merck. ClinicalTrials.gov Identifier: NCT00838929.
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